

CORRECTION OPEN



# Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

C. Hage, V. Rausch, N. Giese, T. Giese, F. Schönsiegel, S. Labsch, C. Nwaeburu, J. Mattern, J. Gladkich and I. Herr

© The Author(s) 2024

*Cell Death and Disease* (2024)15:96; <https://doi.org/10.1038/s41419-023-06385-9>Correction to: *Cell Death and Disease* <https://doi.org/10.1038/cddis.2013.158>, published online 09 May 2013

An image was mistakenly switched in Figure 5B during graphical figure assembly. I would like to emphasize that this image mix-up does not affect the quantitative analysis and the statement of our manuscript in any way. The authors would like to apologize for the confusion.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

